Quality Assessment of Drug Therapy Charles E. Daniels, R.Ph., Ph.D. Pharmacist In Chief Professor of Clinical Pharmacy University of California San Diego, California

March 4, 2010

# **Patient Concerns**

Drug-Drug interaction	70%
Wrong medicine	69%
Cost of treatment	69%
Complications from procedure	69%
Cost of prescription medicines	67%
Hospital acquired infection	49%

ASHP Survey: May 1 and 5, 2002

# IOM Report:

Preventing Medication Errors

# IOM study estimated 1.5 million preventable adverse medication events per year

#### One medication error per patient per day

Photograph of the cover of the report.

Committee on Identifying and Preventing Medication Errors, Philip Aspden, Julie Wolcott, J. Lyle Bootman, Linda R. Cronenwett, Editors. Washington DC; National Academies Press; 2007.

#### **Deaths From Medication Accidents**

Line chart showing the ratio of deaths to 1979 levels by year of death from 1979 through 1998. Chart compares deaths from prescription medicines to railway, motor vehicle, water transport, and air transport accidents. Over time the number of deaths from medication accidents has greatly increased and now greatly exceeds deaths from those other accidents.

Phillips DP, Breder CC, Annu. Rev. Public Health 2002; 23: 135-50

### **Drug Related Morbidity and Mortality Costs**

Hospital\$121 billionLong Term Care33 billionPhysician visits14 billionEmergency visits5 billionAdded prescriptions3 billionTotal\$177 billion

Ernst, J Am Pharm Assn. 2001; 41:192-9 (Mar 2001)

# **Medication Use Quality**

Medication use process/system

Organizational interests in med use

Monitoring and improving med use quality & outcomes

Identifying and reducing med errors

# Adverse Drug Events

Adapted from Bates et al.

#### Adverse Drug Event: preventable or unpredicted medication event---with harm to patient

Graphic illustration showing a large circle entitled "Medication errors (preventable)" with a smaller half-overlapping circle entitled "Adverse Drug Events (ME & ADR)".

# **Cost Impact of ADE's**

	Increased LOS	Increased Cost
ADE	2.2	\$3,244
Preventable ADE	4.6	\$5,857

Bates DW, et al. The Costs of Adverse Drug Events in Hospitalized Patients. <u>JAMA</u>. 1997; 277:307-311

### Incidence of Preventable Drug Related Admissions

Meta-analysis of 15 studies (1980-99)

4.3% (2.5-19%) of all admissions were drug related

>50% of drug related admissions are preventable

Winterstein AG, Sauer BC, Hepler CD, Poole C, Preventable Drug-Related Hospital Admissions. <u>Ann Pharmacother</u> 2002; 36:1238-48

### Impact of Preventable Drug Related Admissions

158 ADR related admissions over 11 months (24% life threatening)

67% inappropriate monitoring of therapy (80% lab abnormality)

26% drug-drug interactions

595 hospital days (6.1 day LOS)

McDonnell PJ and Jacobs MR. Hospital Admissions Resulting from Preventable Adverse Drug Reactions. <u>Ann Pharmacother</u> 2002; 36:1331-6

#### **Medication Errors**

Any <u>preventable</u> event that may cause or lead to inappropriate medication use or patient harm while medication is in the control of the health care professional, patient or consumer

> National Coordinating Council for Medication Error Reporting and Prevention

# Decision to Treat

Flow chart that begins with decision to treat followed by order written and the various stages that the order goes through while being monitored by various health professionals and the patient once it reaches the patient.

# Medical Management Process

Where Adverse Drug Events\* Originate Source Adapted from Bates et al.: JAMA 1995;274:29-34

## Flow chart

As Published in *Computerized Physician Order Entry: Costs, Benefits and Challenges*, Feb 2003, AHA

# **Medication Use Process**

**Complex system** 

**Opportunities for error** 

Impacts patient care and research

# **Process Improvement**

Focus on systems

Data driven

Iterative Cycle Concept

# Shewhart Cycle in Quality Improvement

A circle is shown with arrows showing clockwise motion and numbers 1, 2, 3, 4 evenly spaced inside the circle. The following explains this graphic illustration.

**<u>Step 1:</u>** Planning stage (identify objectives, define data which may be available, define new data needs, plan change or test)

**<u>Step 2:</u>** Implementation or pilot stage (complete the planned changes or test)

**<u>Step 3:</u>** Observation stage (collect information on the effect of the planned changes which have been implemented)

<u>Step 4:</u> Evaluation stage (study the results of the changes implemented during this cycle)

The Shewhart cycle is repeated multiple cycles with expected improvements implemented in each new cycle.

# **Organizational Interests**

What to use

When to use it

How to use it

Is it cost-effective

Will it be used safely

# Pharmacy and Therapeutics Committee

Focus for medication related activities within a health care organization

# **P&T Committee Overview**

**Medical Staff Committee** 

Oversight of medication use in the organization

Staff experts in the medication use process

# P & T Committee Role

**Medication related policies** 

Formulary drug selection and review

Evaluate medication use and improve performance

Educate

# **Medication Policy Issues**

Medication selection and quality

**Medication prescribing** 

**Medication administration** 

# Formulary

#### A continuously updated list of medications and related information representing the clinical judgment of physicians, pharmacists, and other experts...

Principles of a Sound Drug Formulary System, 2000

http://www.usp.org/pdf/EN/patientSafety/pSafetySndFormPrinc.pdf

# **Drug Selection**

Safety

**Clinical Effectiveness** 

**Cost Impact** 

### **Preventable ADE's**

Flow chart showing the steps an order goes though including reaching the patient. Specifically, it starts with a order written (56% of errors), then it is interpreted by a nurse and a pharmacist, then it is transcribed to MAR (6% of errors), then prepared and dispensed (4% of errors) and finally administered to the patient (34% of errors).

Bates DW, Cullen DJ, et al., JAMA 1995; 274: 29-34

## **Error Location in Medication Use Process**

MedMARx 2000 Report

Bar chart indicating the percent of errors that occur in medication administration (42%), documentation (27%), dispensing (17%), prescribing (13%) and monitoring (1%).

### **Errors in Medication Administration**

Total Error Rate = 19% Excluding Wrong Time = 10% Barker et al, Arch Int Med 2002

Bar chart indicating the percent that a medication is given at the wrong time (43%), omission (30%), wrong dose (17%), and wrong drug (4%).

# **Errors in ICU Medication Administration**

Med Administration Errors (3.3%)

Vasoactive Drugs (33%)

Sedative / Analgesics (26%)

Wrong Infusion Rate (40%)

#### Pharmacist Involvement cited in low rate

Calabrese et al. Intensive Care Med, 2001; 27:1592-1598

#### **MEDICATION ERROR DEATHS**

FDA Adverse Events Reporting System 1993-98

Error Type	%
Wrong dose	41
Wrong drug	16
Wrong route	9.5

Phillips J, Meam S, Brinker A, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health-sys Pharm, 2001; 58:1835-41

# Sources of Errors and Elements of Defense Against Them

Graphic illustration

Reason J. Human Error. Cambridge, England: Cambridge Univ. Press; 1990

# **Proximal Causes of Medication Errors\***

Lack of knowledge of the drug	Faulty dose checking
Lack of information about the patient Violation of rules	Infusion pump and parenteral delivery problems Inadequate monitoring
Slips and memory lapses	Drug stocking and delivery problems
Transcription errors	Preparation errors
Faulty checking of identification	Lack of standardization
Faulty interaction with other services	

\* Adapted from Leape LL, et al. Systems analysis of adverse drug events. JAMA 1995;274:35-43

#### Latent Medication System Errors Latent Errors

Drawing of a square with round holes of various sizes in it and lines leading from the holes to the following captions:

Handwriting

incomplete information

order transcription

unclear labeling

high workload

etc

### **Workload and Outcomes**

	IP Mortality	30-day Re-admit	LOS	Total Costs
Team admissions that day	1.09*		3.09*	2.31*
Average Census			-5.30*	-5.11*

\*Significant Multivariate House Staff Effects

Ong et al., Arch Intern Med. 2007, 167: 47-52.

### Prescribing Errors by Medication Category

Antimicrobials	40%
Cardiovascular	18%
Gastrointestinal	7%
Narcotic analgesics	7%

Lesar et al. JAMA, 1997

# MedMARx Reports of Actual Error or Harm

#### MedMARx 2000 General

#### Bar chart showing % of

errors involving insulin (9%), heparin (5%) morphine (4%), Warfarin (4%) and potassium Chloride (3%)

#### MedMARx 2006 Pediatric

#### Bar chart showing % of

errors involving Opioids (11.5%) Antimicrobial (7.5%), Antidiabetic (4.5%) and fluid & elec (4.4%)

#### Specific Factors Related to Errors in Medication Prescribing

Decline in renal or hepatic function	13.9%
History of medication allergy	12.1%
Use of abbreviations	11.4%
Incorrect dose calculation	10.8%

Lesar et al. JAMA, 1997

### MEDMARX<sup>™</sup> Reports of Harmful Errors

MEDMARX 2002 Report

Bar chart showing percent overall medication errors (1.5%), and medication errors in Geriatric medicine (3.5%) of which 55% were fatal.

### Safeguard Against Errors in High-Risk Drugs

**Build in System Redundancies Use Fail-Safes Reduce Options Use Forcing Functions** Externalize or Centralize Error-prone Processes Store Medications Appropriately **Screen New Products** Standardize and Simplify Order Communication Limit Access Use Constraints **Use Reminders Standardize Dosing Procedures** Use Differentialization **Screen New Products Standardize and Simplify Order Communication Limit Access Use Constraints Use Reminders Standardize Dosing Procedures Use Differentialization** 

\* Adapted from Cohen MR, Kilo CM. High-Alert Medications: Safeguarding against errors. In Medication Errors. Washington: American Pharmaceutical Association; 1999

## Total Medication Errors by Month

Line chart showing these errors that crept up in numbers over time beginning with approximately 12 errors in June 2001 up to approximately 45 in June 2005.

## **Use of High Level Data**

Shows interesting trends

Better for global evaluation

No detail to work with

# Pitfalls of High Level Data

Cause unclear

Potential false conclusions

#### **Medication Errors by Quarter**

Chart detailing the errors including wrong drug, wrong dose, duplicate dose, wrong route, wrong time, wrong fluid, wrong rate, wrong device, and wrong IV infiltration by quarter. The total number of errors increased over time from 68 in June 2002 to 81 in March 2005.

#### Broad-based Information Sources

Near misses

Patient specific events

Aggregated hospital-wide occurrence data

External medication error data

Hospital quality improvement data

**Therapeutic trends & changes** 

Hospital programmatic information

### Epidemiology of Medication Errors

**Collect the numbers** 

**Read between the lines** 

Look for common threads

Try to link together

#### Admission Order Medication Omissions

Review of ongoing meds not ordered by MD at admission

53% of patients had at least 1 unintended discrepancy

37% had potential for harm

Cornish, Arch Intern Med 2005; 165:424-429

#### Admission Order Medication Omissions

Туре	Frequency
Omission	65
Dose	35
Frequency	24
Incorrect drug	16
Total	140

Cornish, Arch Intern Med 2005; 165:424-429

### IOM Recommendations on: Preventing Medication Errors

Stronger consumer role (self-management)

**Enhance consumer information sources** 

**Complete patient-information & decision support tools** 

Improved drug labeling

Standardize drug-related health information technologies

Broad research agenda on safe and appropriate med use with funding

## **Medication Use Evaluation**

A performance improvement method that focuses on evaluating and improving medication-use processes with the goal of optimal patient outcomes

American Society of Health-System Pharmacists, 1996

#### **Selection of MUE Projects**

known or suspected to cause adverse reactions or drug interactions

affects large number of patients or medication is frequently prescribed

potentially toxic or causes discomfort at normal doses

under consideration for formulary retention, addition, or deletion

expensive

used in patients at high risk for adverse reactions

critical component of care for a specific disease, condition, or procedure

most effective when used in a specific way

suboptimal use would have a negative effect on patient outcomes or system costs

Adapted from American Society of Health-System Pharmacists. ASHP guidelines on medication-use evaluation. Am J Health Syst Phar 1996;53:1953-5. A chart is shown that indicates that during FY 01 through FY 05 the amount spent on anti-infective agents went from \$1,612,016 in FY 01 to \$5,287,206 in FY 05. In addition, the chart indicates that in FY 01 \$1,226,067 was spent on Antineoplastic agents and by FY 05 the amount spent on those agents was \$1,866.450.

Review Category	Data Collection Model (s)	Typical Application	Comments
Retrospect	Data is collected for a fixed ` period which may be archival or accumulation of new patients for a fixed period of time	Data archive search for prescribing patterns of patients on serotonin antagonist antiemetic drugs	Supports large scale epidemiologic approach No active intervention to change medication use patterns occurs due to the post-hoc data collection process
Concurrent	Each new order generates an automatic review of previously approved criteria for use within a specified period of the initiation of therapy	Review of naloxone to investigate possible nosocomial adverse medication event	
	Laboratory or other monitoring criteria are reported for all patients on the drug	Digoxin monitoring based upon daily review of digoxin serum levels (49).	
	Abnormal Laboratory or other monitoring criteria are reported for all patients on the drug on a regular basis.	Regular review of serum creatinine for patients on aminoglycosides	
	Each new order for the drug is evaluated for compliance with previously approved criteria for use. Variance to the criteria require intervention prior to initiation of therapy	Medication use guidelines (ketorolac) (50); Restricted antibiotics	

### **Evidence Based Guidelines**

Photograph of a Fact Sheet on Beta-Blockers for Acute Myocardial Infarction dated April 27, 2005

www.guidelines.gov

### Benchmarking

Primary Indication for NovoSeven<sup>TM</sup> Use

37.8% (119/315) of patients received NovoSeven for prevention of bleed

62.2% (196/315) of patients received NovoSeven for treatment of active bleed

Primary Indication for NovoSeven Use by Institution

Bar chart showing % of cases. The numbers above the bars represent the number of complete cases submitted by each institution.

#### Benchmarking

Chart showing C6- Medication until first dose of antifungal medication – Page 1 of 2

# Benchmarking

Photograph of a document called Key Indicator Report – Sample Hospital, July-September 2005 (Q3)

Photograph of a Quality Report for a Hospital.

National Quality Improvement Goals. Condition: Heart Attack Care Reporting Period: July, 2004 – June, 2005

## Computerized Laboratory Alerts

**Flashing Computerized Alert for low Potassium** 

Increased follow-up monitoring

Increased K+ intervention rate

Decreased hypokalemia at discharge

Paltiel, Arch Intern Med 2003; 163:200-204

# **Computerized Order Entry**

Taylor (Pediatrics, 2008)

Feldstein (Arch Intern Med, 2006)

Mekhjian (JAMIA, 2002)

Nightingale (BMJ, 2000)

Bates (JAMA, 1998; JAMIA, 1999)

Raschke (JAMA, 1998)

Claussen (Ann Intern Med, 1996)

#### Computer Facilitated Order Errors

Computerized prescriber order entry error opportunities

22 types of errors facilitated by CPOE system

Many can be corrected by investigation and improvement

Koppel, JAMA 2005; 1197-1203

### **Computer Facilitated Errors**

20% of MedMARx reports involved computer related interaction

71% did not reach patient

0.74% did actual harm

Automated dispensing machines

MedMARx 5th Anniversary Data Report, 2005

### Simulation of Technology Impact

Computer simulation of integrated medication use system

<u>Concluded</u> 1,226 days of excess hospitalization

#### \$1.4 million associated costs

Anderson, JAMIA 2002; 9: 479-90

# **Drug Name Selection**

Lambert (Drug Safety, 2005)

Lambert (AJHP, 1997)

Lambert (Medical Care, 1999

## Summary of Medication Use Quality Issues

Complex process prone to error

Drug use can be improved

ADE risks can be reduced

Photograph of various medications (tablets, capsules, and vials).